197 related articles for article (PubMed ID: 19646431)
1. Enhancing prostate cancer cryotherapy using tumour necrosis factor related apoptosis-inducing ligand (TRAIL) sensitisation in an in vitro cryotherapy model.
Ismail M; Morgan R; Harrington K; Davies J; Pandha H
Cryobiology; 2009 Oct; 59(2):207-13. PubMed ID: 19646431
[TBL] [Abstract][Full Text] [Related]
2. Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer.
Clarke DM; Robilotto AT; VanBuskirk RG; Baust JG; Gage AA; Baust JM
Prostate Cancer Prostatic Dis; 2007; 10(2):175-84. PubMed ID: 17297503
[TBL] [Abstract][Full Text] [Related]
3. Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer.
Clarke DM; Baust JM; Van Buskirk RG; Baust JG
Cryobiology; 2001 Jun; 42(4):274-85. PubMed ID: 11748936
[TBL] [Abstract][Full Text] [Related]
4. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
Zhang X; Li W; Olumi AF
Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199
[TBL] [Abstract][Full Text] [Related]
5. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
[TBL] [Abstract][Full Text] [Related]
6. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
[TBL] [Abstract][Full Text] [Related]
7. Is TRAIL the holy grail of cancer therapy?
Newsom-Davis T; Prieske S; Walczak H
Apoptosis; 2009 Apr; 14(4):607-23. PubMed ID: 19194800
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
Frese S; Schüller A; Frese-Schaper M; Gugger M; Schmid RA
Anticancer Res; 2009 Aug; 29(8):2905-11. PubMed ID: 19661294
[TBL] [Abstract][Full Text] [Related]
9. Cryosurgery--a putative approach to molecular-based optimization.
Baust JG; Gage AA; Clarke D; Baust JM; Van Buskirk R
Cryobiology; 2004 Apr; 48(2):190-204. PubMed ID: 15094094
[TBL] [Abstract][Full Text] [Related]
10. Cryosurgical technique: assessment of the fundamental variables using human prostate cancer model systems.
Klossner DP; Robilotto AT; Clarke DM; VanBuskirk RG; Baust JM; Gage AA; Baust JG
Cryobiology; 2007 Dec; 55(3):189-99. PubMed ID: 17888898
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Elders RC; Baines SJ; Catchpole B
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):11-6. PubMed ID: 19185923
[TBL] [Abstract][Full Text] [Related]
12. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature.
Van Ophoven A; Ng CP; Patel B; Bonavida B; Belldegrun A
Prostate Cancer Prostatic Dis; 1999 Dec; 2(5/6):227-233. PubMed ID: 12497168
[TBL] [Abstract][Full Text] [Related]
14. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
15. Overcoming resistance to trail-induced apoptosis in prostate cancer by regulation of c-FLIP.
Zhang X; Li W; Olumi AF
Methods Enzymol; 2008; 446():333-49. PubMed ID: 18603132
[TBL] [Abstract][Full Text] [Related]
16. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells.
Chen L; Chen D; Gong M; Na M; Li L; Wu H; Jiang L; Qian Y; Fang G; Xue X
Cancer Lett; 2009 Nov; 284(2):141-8. PubMed ID: 19447545
[TBL] [Abstract][Full Text] [Related]
17. Effect of UV irradiation on colorectal cancer cells with acquired TRAIL resistance.
Kim SC; Park SS; Lee YJ
J Cell Biochem; 2008 Jul; 104(4):1172-80. PubMed ID: 18247342
[TBL] [Abstract][Full Text] [Related]
18. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B.
Tang W; Wang W; Zhang Y; Liu S; Liu Y; Zheng D
FEBS J; 2009 Jan; 276(2):581-93. PubMed ID: 19120450
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues.
Sanlioglu AD; Koksal IT; Ciftcioglu A; Baykara M; Luleci G; Sanlioglu S
J Urol; 2007 Jan; 177(1):359-64. PubMed ID: 17162091
[TBL] [Abstract][Full Text] [Related]
20. The effect of TRAIL molecule on cell viability in in vitro beta cell culture.
Tekmen I; Ozyurt D; Pekçetin C; Buldan Z
Acta Diabetol; 2007 Jun; 44(2):60-4. PubMed ID: 17530468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
